Dr. Yasmeen Rauf
Claim this profileUNC Lineberger Comprehensive Cancer Center
Area of expertise
Glioblastoma
Yasmeen Rauf has run 4 trials for Glioblastoma. Some of their research focus areas include:
Brain Tumor
Yasmeen Rauf has run 3 trials for Brain Tumor. Some of their research focus areas include:
Affiliated Hospitals
UNC Lineberger Comprehensive Cancer Center
University Of North Carolina (UNC) - Chapel Hill
Clinical Trials Yasmeen Rauf is currently running
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting
2 awards
Phase 3
4 criteria
CAR-T Cell Therapy
for Glioblastoma
The purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food and Drug Administration for glioblastoma.
Recruiting
1 award
Phase 1
More about Yasmeen Rauf
Clinical Trial Related
6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Yasmeen Rauf has experience with
- Temozolomide
- CAR.B7-H3T Cells
- IGV-001
- Placebo
- Standard Of Care (SOC): Radiation Therapy
- Olaparib
Breakdown of trials Yasmeen Rauf has run
Glioblastoma
Brain Tumor
Bile Duct Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yasmeen Rauf specialize in?
Yasmeen Rauf focuses on Glioblastoma and Brain Tumor. In particular, much of their work with Glioblastoma has involved Stage IV patients, or patients who are Stage III.
Is Yasmeen Rauf currently recruiting for clinical trials?
Yes, Yasmeen Rauf is currently recruiting for 2 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Yasmeen Rauf has studied deeply?
Yes, Yasmeen Rauf has studied treatments such as Temozolomide, CAR.B7-H3T cells, IGV-001.
What is the best way to schedule an appointment with Yasmeen Rauf?
Apply for one of the trials that Yasmeen Rauf is conducting.
What is the office address of Yasmeen Rauf?
The office of Yasmeen Rauf is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.